Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Status:
Completed
Trial end date:
2018-07-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and effectiveness of oral vismodegib
therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC).
The term 'histologic subtype' refers to how the cells and tumor tissue looks under the
microscope. Three different 'histologic subtypes' of basal cell skin cancer
(infiltrative/morpheaform, nodular and superficial) will be examined in this study.